Evidence map›Paper›PMID 36358238›Full record

ArticleAntibiotics (Basel, Switzerland)2022

Evaluation of Fosfomycin-Sulbactam Combination Therapy against Carbapenem-Resistant

Sazlyna Mohd Sazlly Lim, Aaron Heffernan, Saiyuri Naicker, Steven Wallis, Jason A Roberts, Fekade Bruck Sime

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06440304 (Therapeutic Strategies for Carbapenem-Resistant Acinetobacter Baumannii Infections), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06440304 phase4recruitingnot on this mapstarted 2025, after this paper: background citation

Therapeutic Strategies for Carbapenem-Resistant Acinetobacter Baumannii Infections: Study Protocol

TypeinterventionalSponsorClinical Hospital Centre ZagrebRan2025 to 2027Enrolled108ConditionsInfections, Bacterial, Sepsis BacterialArmsFosfomycin, Eravacycline, ampicillin/sulbactam
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. The challenges of difficult-to-treatClinical microbiology reviews · 2024
    Review
  4. Antibiotic Treatment of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2024
    Review
  5. Treatment Strategies of Colistin ResistanceAntibiotics (Basel, Switzerland) · 2024
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Sazlyna Mohd Sazlly LimUQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Brisbane, QLD 4029, Australia.
Aaron HeffernanUQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Brisbane, QLD 4029, Australia.
Saiyuri NaickerUQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Brisbane, QLD 4029, Australia.
Steven WallisUQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Brisbane, QLD 4029, Australia.
Jason A RobertsUQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Brisbane, QLD 4029, Australia.ORCID 0000-0001-6218-435X
Fekade Bruck SimeUQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Brisbane, QLD 4029, Australia.ORCID 0000-0003-4061-2063
The University of Queensland · AUGriffith University · AUUniversiti Putra Malaysia · MY

Funding

National Health and Medical Research Council APP1099452
6 · The paper itself

Abstract

Static concentration in vitro studies have demonstrated that fosfomycin- or sulbactam-based combinations may be efficacious against carbapenem-resistant

Indexed as

Acinetobacter baumanniicarbapenem-resistantcombinationfosfomycinhollow-fibre infection modelpharmacodynamicsulbactam

Identifiers

PMID36358238
PMCPMC9686642
OpenAlexW4308772999

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.